Want to see LRMR full AI Analyst Report?
LRMR Stock Chart & Stats
$4.00
-$0.11(-2.75%)
At close: 4:00 PM EDT
$4.00
-$0.11(-2.75%)
Day’s Range― - ―
52-Week Range$2.72 - $6.42
Previous CloseN/A
Volume458.18K
Average Volume (3M)2.47M
Market Cap
$434.23M
Enterprise Value$167.06
Total Cash (Recent Filing)$156.27M
Total Debt (Recent Filing)$4.96M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 05, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding103,882,935
10 Day Avg. Volume1,373,940
30 Day Avg. Volume2,472,096
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.33Price Target Upside208.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: Rolling BLAFDA alignment on a rolling BLA using skin frataxin as a surrogate and submission of the first module materially reduces regulatory uncertainty and creates a clear, accelerated path to potential approval. This structural milestone increases program de-risking and timelines for commercial planning.
Durable Biomarker & Clinical SignalsConsistent, durable increases in skin frataxin and directional functional improvements across 18 months supply a biologically plausible surrogate and supportive efficacy signals. This strengthens the scientific case for accelerated pathways and raises the chance that confirmatory trials will validate clinical benefit.
Low Leverage / Modest DebtA relatively low debt burden reduces near-term solvency and interest-coverage pressure, preserving financial flexibility. For a pre-revenue biotech, low leverage makes it easier to manage funding rounds and pursue strategic options without immediate covenant or refinancing stress.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-revenue with consistently expanding net losses, reflecting rising R&D and readiness spending. Persistent negative earnings mean long-term value depends entirely on clinical/regulatory success and future commercialization, heightening execution and financing risk for investors.
High And Accelerating Cash BurnRapidly increasing operating cash outflows materially shorten runway absent financings. Even with recent cash balances, this burn trajectory makes periodic equity or other capital raises likely, which can disrupt long-term R&D plans and create dependency on external funding conditions.
Expanded Authorized Shares; Dilution RiskApproval to nearly double authorized shares provides capital-raising flexibility but structurally raises dilution risk for existing holders. Given pre-revenue status and rising cash needs, the company is more likely to issue equity, which can materially affect long-term per-share economics and returns.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.71 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $434.23M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.381 by $0.081.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.381. Following the earnings report the stock price went up 3.266%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (208.33% Upside)
$12.33 (208.33% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 162.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $166.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.21%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR Stock 12 Month Forecast
Average Price Target
$12.33
▲(208.33% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
35.99% Insiders
5.48% Mutual Funds
10.02% Other Institutional Investors
40.06% Public Companies and Individual Investors